skip to Main Content

Drug Development in Pancreatic Cancer: An Update on Novel Therapies

Newsfeed image, light gray text on dark gray background
Pancreatic ductal adenocarcinoma (PDAC) carries a high mortality rate and is the fourth leading cause of cancer-related mortality in the United States.

Prior to 2011, the treatment for PDAC was mainly gemcitabine in both the adjuvant and palliative setting. However, two landmark studies established FOLFIRINOX and protein-bound paclitaxel and gemcitabine as frontline regimens for the treatment of metastatic PDAC.2,3   Read more . . . 

Back To Top